| Literature DB >> 25874130 |
Bancha Satirapoj1, Pamila Tasanavipas1, Ouppatham Supasyndh1.
Abstract
A total of 244 patients with lupus nephritis (219 women (89.8%) with a female to male ratio of 9 : 1) were included in the study. Clinical and laboratory findings at renal biopsy are clinically valuable in identifying different renal classifications of lupus pathology, activity, and chronicity index. Patients with class IVG had significantly higher proportions of microscopic hematuria, proteinuria, hypertension, impaired renal function, anemia, hypoalbuminuria, and positive anti-DNA antibody. All of these findings correlated well with high activity index and chronicity index of lupus pathology. Considering these correlations may help to determine the clinicopathologic status of lupus patients.Entities:
Year: 2015 PMID: 25874130 PMCID: PMC4383344 DOI: 10.1155/2015/857316
Source DB: PubMed Journal: Int J Nephrol
The demographic and clinical findings at renal biopsy by LN class.
| Total | Class II | Class III | Class IVG | Class IVS | Class V | |
|---|---|---|---|---|---|---|
| Female ( | 219 (89.8%) | 5 (71.4%) | 35 (92.1%) | 106 (90.6%) | 34 (87.2%) | 39 (90.7%) |
| Age (years) | 34 ± 12 | 42 ± 9.8 | 34.7 ± 13.2 | 32 ± 11.4† | 33 ± 11.1 | 38.6 ± 12.5 |
| Current immunosuppressive agents ( | ||||||
| Prednisolone | 226 (92.6%) | 6 (85.7%) | 37 (97.4%) | 104 (88.9%) | 38 (97.4%) | 41 (95.3%) |
| Azathioprine | 72 (29.5%) | 2 (28.6%) | 9 (23.7%) | 31 (26.5%) | 14 (35.9%) | 16 (37.2%) |
| Cyclophosphamide | 85 (34.8%) | 2 (28.6%) | 14 (36.8%) | 40 (34.2%) | 13 (33.3%) | 16 (37.2%) |
| Mycophenolate mofetil | 39 (16%) | 1 (14.3%) | 8 (21.1%) | 19 (16.2%) | 7 (17.9%) | 4 (9.3%) |
| Current antihypertensive agents ( | ||||||
| ACEI/ARB | 102 (41.8%) | 4 (57.1%) | 12 (31.6%) | 45 (38.5%) | 19 (48.7%) | 22 (51.2%) |
| CCB | 59 (24.2%) | 3 (42.9%) | 3 (7.9%)* | 36 (30.8%) | 9 (23.1%) | 8 (18.6%) |
| BB | 15 (6.1%) | — | — | 8 (6.8%) | 5 (12.8%) | 2 (4.7%) |
| Extrarenal manifestation ( | ||||||
| Arthritis | 134 (54.9%) | 2 (28.6%) | 28 (73.7%) | 59 (50.4%) | 20 (51.3%) | 25 (58.1%) |
| Malar rash | 112 (45.9%) | 2 (28.6%) | 16 (42.1%) | 57 (48.7%) | 20 (51.3%) | 17 (39.5%) |
| Discoid rash | 60 (24.6%) | 1 (14.3%) | 6 (15.8%) | 28 (23.9%) | 10 (25.6%) | 15 (34.9%) |
| Photosensitivity rash | 45 (18.4%) | 1 (14.3%) | 7 (18.4%) | 20 (17.1%) | 8 (20.5%) | 9 (20.9%) |
| Oral ulcer | 66 (27%) | — | 11 (28.9%) | 39 (33.3%) | 6 (15.4%) | 10 (23.3%) |
| AIHA | 79 (32.4%) | — | 13 (34.2%) | 45 (38.5%) | 10 (25.6%) | 11 (25.6%) |
| Leukopenia | 86 (35.2%) | 1 (14.3%) | 18 (47.4%) | 44 (37.6%) | 11 (28.2%) | 12 (27.9%) |
| Thrombocytopenia | 64 (26.2%) | 1 (14.3%) | 8 (21.1%) | 30 (25.6%) | 14 (35.9%) | 11 (25.6%) |
| Serositis | 50 (20.5%) | — | 6 (15.8%) | 32 (27.6%) | 8 (20.5%) | 4 (9.3%) |
| CNS | 11 (4.5%) | — | — | 7 (6%) | — | 4 (9.3%) |
Data are mean ± SD, median with interquartile range and percentages; † P < 0.05 versus class V and * P < 0.05 versus class II. ACEI: angiotensin converting enzyme inhibitor, AIHA: autoimmune hemolytic anemia, ARB: angiotensin type 1 receptor blocker, BB: beta-blockers, CCB: calcium channel blocker, CNS: central nervous system.
Renal findings at renal biopsy by LN class.
| Total | Class II | Class III | Class IVG | Class IVS | Class V | |
|---|---|---|---|---|---|---|
| Levels of clinical and laboratory findings | ||||||
| SBP (mmHg) | 138.9 ± 22.7 | 118.4 ± 14.7 | 131.1 ± 17.9 | 144.2 ± 22.8* | 139.3 ± 22.3* | 134.6 ± 23.9 |
| DBP (mmHg) | 85.8 ± 14.4 | 76.1 ± 10.7 | 81 ± 12.1 | 89.5 ± 14.2†∗ | 86.1 ± 14.8 | 81.1 ± 13.9 |
| Hemoglobin (g/dL) | 10.7 ± 2.2 | 12.5 ± 1.3 | 11.2 ± 2.2 | 10 ± 2.2†∗ | 10.7 ± 1.5† | 12 ± 1.9 |
| BUN (mg/dL) | 27.9 ± 21.4 | 14.7 ± 4.7 | 18.4 ± 12.3 | 33.5 ± 24.3†∗ | 28.8 ± 17.4 | 22.2 ± 19.6 |
| Serum creatinine (mg/dL) | 1.3 ± 1 | 1.2 ± 0.8 | 0.9 ± 0.5 | 1.5 ± 1.1† | 1.3 ± 1 | 1.1 ± 1.1 |
| Estimated GFR (mL/min/1.73 m2) | 80.2 ± 38.3 | 76 ± 32.4 | 98.2 ± 31.7 | 68.4 ± 37.2† | 82 ± 36.9 | 95.3 ± 38.2 |
| Serum cholesterol (mg/dL) | 287.2 ± 107.6 | 225.7 ± 45.7 | 249.5 ± 74.5 | 296.2 ± 105.6 | 302 ± 138.3 | 297.3 ± 113.9 |
| Serum albumin (g/dL) | 2.9 ± 0.7 | 3.9 ± 0.5 | 3 ± 0.8* | 2.8 ± 0.6* | 2.9 ± 0.6* | 2.9 ± 0.6* |
| UPCR (g/g creatinine) | 4.4 ± 3.2 | 1.3 ± 0.5† | 3.4 ± 2.4* | 4.7 ± 3.3* | 4.2 ± 2.4* | 5.1 ± 3.8* |
| Percentages of clinical and laboratory findings | ||||||
| Hypertension ( | 163 (66.8%) | 3 (42.9%) | 18 (47.4%) | 92 (78.6%)† | 26 (66.7%) | 24 (55.8%) |
| Microscopic hematuria ( | 157 (64.3%) | 4 (57.1%) | 24 (63.2%)† | 86 (73.5%)† | 29 (74.4%)† | 14 (32.6%) |
| GFR < 50 mL/min/1.73 m2 | 68 (27.9%) | 2 (28.6%) | 5 (13.2%) | 44 (37.6%)† | 10 (25.6%) | 7 (16.3%) |
| Nephrotic range proteinuria ( | 125 (51.2%) | — | 14 (36.8%) | 67 (57.3%)* | 19 (48.7%)* | 25 (58.1%)* |
| Nephrotic syndrome ( | 74 (30.3%) | — | 7 (18.4%) | 39 (33.3%)* | 10 (25.6%) | 18 (41.9%)* |
| Anti-dsDNA ( | 190 (77.9%) | 3 (42.9%) | 33 (86.8%)* | 92 (80.7%)* | 32 (86.5%)* | 30 (69.8%) |
Data are mean ± SD, median with interquartile range and percentages; † P < 0.05 versus class V and * P < 0.05 versus class II. BUN: blood urea nitrogen, DBP: diastolic blood pressure, and GFR: glomerular filtration rate. UPCR: urine protein creatinine ratio and SBP: systolic blood pressure.
The renal pathological findings at renal biopsy by LN class.
| Total | Class II | Class III | Class IVG | Class IVS | Class V | |
|---|---|---|---|---|---|---|
| Activity index | ||||||
| Endocapillary proliferation | 184 (75.4%) | 1 (14.3%) | 34 (89.5%)†∗ | 108 (92.3%)†∗ | 39 (100%)†∗ | 2 (4.7%) |
| Glomerular leukocyte infiltration | 148 (60.7%) | 1 (14.3%) | 20 (52.6%)†∗ | 92 (78.6%)†∗ | 30 (76.9%)†∗ | 5 (11.6%) |
| Hyaline thrombi | 154 (63.1%) | 0 (0%) | 17 (44.7%)†∗ | 100 (85.5%)†∗ | 33 (84.6%)†∗ | 4 (9.3%) |
| Fibrinoid necrosis | 41 (16.8%) | 1 (14.3%) | 6 (15.8%) | 23 (19.7%)† | 11 (28.2%)† | 0 (0%) |
| Cellular crescent | 94 (38.5%) | 0 (0%) | 15 (39.5%)† | 58 (49.6%)†∗ | 20 (51.3%)†∗ | 1 (2.3%) |
| Interstitial inflammation | 150 (61.5%) | 3 (42.9%) | 22 (57.9%) | 78 (66.7%)† | 28 (71.8%) | 19 (44.2%) |
| Total activity index (Max 24) | 6.8 ± 4.3 | 1.1 ± 2.2 | 4.4 ± 2.3†∗ | 9.4 ± 3.1†∗ | 8.6 ± 2.9†∗ | 1.2 ± 1.8 |
| Median (IQR) | 7 (3, 10) | 0 (0, 1) | 4 (3, 6) | 9 (7, 11.5) | 8 (6, 11) | 1 (0, 1) |
| Chronicity index | ||||||
| Sclerotic glomeruli | 121 (49.6%) | 4 (57.1%) | 16 (42.1%) | 55 (47%) | 26 (66.7%) | 20 (46.5%) |
| Fibrous crescent | 53 (21.7%) | 0 (0%) | 5 (13.2%) | 33 (28.2%)† | 15 (38.5%)†∗ | 0 (0%) |
| Tubular atrophy | 121 (49.6%) | 1 (14.3%) | 12 (31.6%) | 64 (54.7%) | 23 (59%)* | 21 (48.8%) |
| Interstitial fibrosis | 139 (57%) | 1 (14.3%) | 14 (36.8%) | 73 (62.4%)* | 27 (69.2%)* | 24 (55.8%) |
| Total chronicity index (Max 12) | 2.5 ± 2.3 | 1.1 ± 1.5 | 1.6 ± 1.9 | 2.9 ± 2.4 | 3 ± 2.1* | 2.2 ± 2.3 |
| Median (IQR) | 2 (0, 4) | 1 (0, 2) | 1 (0, 3) | 3 (1, 4) | 3 (2, 4) | 2 (0, 3) |
Data are mean ± SD, median with interquartile range and percentages; † P < 0.05 versus class V and * P < 0.05 versus class II.
Univariate and multivariate regression analyses demonstrating clinical factors showing correlation with renal pathological activity index (AI).
| Univariate regression |
Multivariate regression | |||||
|---|---|---|---|---|---|---|
| Beta | SE. |
| Beta | SE. |
| |
| Age (yrs) | −0.09 | 0.02 | <0.001 | −0.10 | 0.02 | <0.001 |
| SBP (mmHg) | 0.05 | 0.01 | <0.001 | |||
| DBP (mmHg) | 0.08 | 0.02 | <0.001 | 0.05 | 0.02 | 0.001 |
| Serositis | 1.97 | 0.68 | 0.004 | |||
| Anti-dsDNA | 2.23 | 0.69 | 0.001 | 1.18 | 0.57 | 0.039 |
| Blood urea nitrogen (mg/dL) | 0.08 | 0.01 | <0.001 | |||
| Serum creatinine (mg/dL) | 1.43 | 0.27 | <0.001 | −0.98 | 0.43 | 0.024 |
| Estimated GFR (mL/min/1.73 m2) | −0.04 | 0.01 | <0.001 | −0.05 | 0.01 | <0.001 |
| Hemoglobin (g/dL) | −0.81 | 0.12 | <0.001 | −0.40 | 0.12 | 0.001 |
| Serum albumin (g/dL) | −1.21 | 0.40 | 0.003 | |||
| UPCR (g/g creatinine) | 0.21 | 0.09 | 0.016 | 0.18 | 0.07 | 0.014 |
| Microscopic hematuria | 2.50 | 0.56 | <0.001 | 1.44 | 0.48 | 0.003 |
Independent variables in the multivariate model were chosen using a stepwise regression analysis where all significant variables listed in the univariate analysis were included.
DBP: diastolic blood pressure, GFR: glomerular filtration rate, SBP: systolic blood pressure, and UPCR: urine protein creatinine ratio.
Univariate and multivariate regression analyses demonstrating clinical factors showing correlation with renal pathological chronicity index (CI).
| Univariate regression |
Multivariate regression | |||||
|---|---|---|---|---|---|---|
| Beta | SE. |
| Beta | SE. |
| |
| Age (yrs) | 0.01 | 0.01 | 0.762 | |||
| SBP (mmHg) | 0.02 | 0.01 | 0.001 | |||
| DBP (mmHg) | 0.03 | 0.01 | 0.006 | |||
| Serositis | 0.86 | 0.37 | 0.020 | |||
| Anti-dsDNA | 0.64 | 0.38 | 0.092 | 0.67 | 0.30 | 0.026 |
| Blood urea nitrogen (mg/dL) | 0.04 | 0.01 | <0.001 | |||
| Serum creatinine (mg/dL) | 1.17 | 0.13 | <0.001 | 0.62 | 0.21 | 0.004 |
| Estimated GFR (mL/min/1.73 m2) | −0.03 | 0.00 | <0.001 | −0.02 | 0.01 | 0.008 |
| Hemoglobin (g/dL) | −0.37 | 0.07 | <0.001 | −0.20 | 0.06 | 0.002 |
| Serum albumin (g/dL) | −0.39 | 0.22 | 0.077 | |||
| UPCR (g/g creatinine) | 0.13 | 0.05 | 0.005 | 0.12 | 0.04 | 0.003 |
| Microscopic hematuria | −0.58 | 0.31 | 0.063 | −1.06 | 0.26 | <0.001 |
Independent variables in the multivariate model were chosen using a stepwise regression analysis where all significant variables listed in the univariate analysis were included.
DBP: diastolic blood pressure, GFR: glomerular filtration rate, SBP: systolic blood pressure, and UPCR: urine protein creatinine ratio.